Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT00257972




Registration number
NCT00257972
Ethics application status
Date submitted
23/11/2005
Date registered
24/11/2005
Date last updated
8/11/2013

Titles & IDs
Public title
Study of Aripiprazole in Patients With Bipolar I Disorder
Scientific title
Efficacy of Aripiprazole in Combination With Valproate or Lithium in the Treatment of Mania in Patients With Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy
Secondary ID [1] 0 0
CN138-134
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Bipolar Disorder 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Other mental health disorders
Mental Health 0 0 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - aripiprazole

Treatment: Drugs: aripiprazole
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline to endpoint in a mania rating scale
Timepoint [1] 0 0
Secondary outcome [1] 0 0
Response rate and Clinical Global Impression Scale at endpoint
Timepoint [1] 0 0

Eligibility
Key inclusion criteria
- Clinical diagnosis of bipolar I disorder, manic or mixed episode
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- First manic or mixed episode

- Allergic, intolerant, or unresponsive to lithium and valproate or to aripiprazole

- Participation in a previous clinical trial within the past month or ever participated
in a trial with aripiprazole

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2004
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/12/2007
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Local Institution - Epping
Recruitment postcode(s) [1] 0 0
- Epping
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Rousse
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Sofia
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Varna
Country [18] 0 0
Czech Republic
State/province [18] 0 0
Brno - Bohunice
Country [19] 0 0
Czech Republic
State/province [19] 0 0
Hradec Kralove
Country [20] 0 0
Czech Republic
State/province [20] 0 0
Opava
Country [21] 0 0
Czech Republic
State/province [21] 0 0
Praha 2
Country [22] 0 0
Estonia
State/province [22] 0 0
Parnu
Country [23] 0 0
Estonia
State/province [23] 0 0
Tallinn
Country [24] 0 0
Estonia
State/province [24] 0 0
Tartu
Country [25] 0 0
Estonia
State/province [25] 0 0
Viljandi Maakond
Country [26] 0 0
Estonia
State/province [26] 0 0
Voru Maakond
Country [27] 0 0
France
State/province [27] 0 0
Bordeaux
Country [28] 0 0
France
State/province [28] 0 0
Dole
Country [29] 0 0
France
State/province [29] 0 0
Grenoble
Country [30] 0 0
France
State/province [30] 0 0
Jonzac Cedex
Country [31] 0 0
France
State/province [31] 0 0
La Rochelle Cedex 1
Country [32] 0 0
France
State/province [32] 0 0
Limoges Cedex
Country [33] 0 0
France
State/province [33] 0 0
Marseille Cedex 05
Country [34] 0 0
France
State/province [34] 0 0
Nimes
Country [35] 0 0
France
State/province [35] 0 0
Pessac
Country [36] 0 0
France
State/province [36] 0 0
Rennes Cedex
Country [37] 0 0
Germany
State/province [37] 0 0
Berlin
Country [38] 0 0
Germany
State/province [38] 0 0
Jena
Country [39] 0 0
Germany
State/province [39] 0 0
Magdeburg
Country [40] 0 0
Germany
State/province [40] 0 0
Meunchen
Country [41] 0 0
Germany
State/province [41] 0 0
Westersted
Country [42] 0 0
Hungary
State/province [42] 0 0
Budapest
Country [43] 0 0
Hungary
State/province [43] 0 0
Gyula
Country [44] 0 0
Hungary
State/province [44] 0 0
Kecskemet
Country [45] 0 0
Hungary
State/province [45] 0 0
Nagykallo
Country [46] 0 0
Italy
State/province [46] 0 0
Bassano Del Grappa
Country [47] 0 0
Italy
State/province [47] 0 0
Cagliari
Country [48] 0 0
Italy
State/province [48] 0 0
Firenze
Country [49] 0 0
Italy
State/province [49] 0 0
Pisa
Country [50] 0 0
Italy
State/province [50] 0 0
Roma
Country [51] 0 0
Italy
State/province [51] 0 0
Sassari
Country [52] 0 0
Italy
State/province [52] 0 0
Trieste
Country [53] 0 0
Italy
State/province [53] 0 0
Voghera -Pavia
Country [54] 0 0
Netherlands
State/province [54] 0 0
Retranchement
Country [55] 0 0
Netherlands
State/province [55] 0 0
Zaandam
Country [56] 0 0
Poland
State/province [56] 0 0
Choroszcz
Country [57] 0 0
Poland
State/province [57] 0 0
Koscian
Country [58] 0 0
Poland
State/province [58] 0 0
Krakow
Country [59] 0 0
Poland
State/province [59] 0 0
Poznan
Country [60] 0 0
Poland
State/province [60] 0 0
Torun
Country [61] 0 0
Poland
State/province [61] 0 0
Tuszyn
Country [62] 0 0
Portugal
State/province [62] 0 0
Lisboa
Country [63] 0 0
Portugal
State/province [63] 0 0
Lisbon
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Leningrad Region
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Moscow
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Saint Petersburg
Country [67] 0 0
Russian Federation
State/province [67] 0 0
Smolensk
Country [68] 0 0
South Africa
State/province [68] 0 0
Eastern Cape
Country [69] 0 0
South Africa
State/province [69] 0 0
Free State
Country [70] 0 0
South Africa
State/province [70] 0 0
Gauteng
Country [71] 0 0
South Africa
State/province [71] 0 0
Kwa Zulu Natal
Country [72] 0 0
South Africa
State/province [72] 0 0
Western Cape
Country [73] 0 0
Spain
State/province [73] 0 0
Barcelona
Country [74] 0 0
Spain
State/province [74] 0 0
Madrid
Country [75] 0 0
Spain
State/province [75] 0 0
Valencia
Country [76] 0 0
Spain
State/province [76] 0 0
Vitoria
Country [77] 0 0
Switzerland
State/province [77] 0 0
Herisau
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Dumbartonshire
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Greater London
Country [80] 0 0
United Kingdom
State/province [80] 0 0
Lancashire
Country [81] 0 0
United Kingdom
State/province [81] 0 0
Mid Glamorgan
Country [82] 0 0
United Kingdom
State/province [82] 0 0
Middlesex

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Otsuka Pharmaceutical Development & Commercialization, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Otsuka America Pharmaceutical
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this research study is to compare the efficacy of aripiprazole with placebo in
combination with lithium or valproate monotherapy, in the treatment of bipolar I patients
with manic or mixed episodes.
Trial website
https://clinicaltrials.gov/ct2/show/NCT00257972
Trial related presentations / publications
Vieta E, T'joen C, McQuade RD, Carson WH Jr, Marcus RN, Sanchez R, Owen R, Nameche L. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008 Oct;165(10):1316-25. doi: 10.1176/appi.ajp.2008.07101560. Epub 2008 Apr 1.
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT00257972